These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 29952225)

  • 1. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
    Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
    J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
    Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
    Gelfand JM; Wan J; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Stierstorfer MB; Brod BA; Schleicher SM; Bebo BF; Troxel AB; Shin DB; Steinemann JM; Goldfarb J; Yeung H; Van Voorhees AS
    Arch Dermatol; 2012 Apr; 148(4):487-94. PubMed ID: 22508874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ; Bello-Quintero CE
    J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
    Armstrong AW; Robertson AD; Wu J; Schupp C; Lebwohl MG
    JAMA Dermatol; 2013 Oct; 149(10):1180-5. PubMed ID: 23945732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
    Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
    Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics for the primary care physician: Review and treatment of psoriasis.
    Schadler ED; Ortel B; Mehlis SL
    Dis Mon; 2019 Mar; 65(3):51-90. PubMed ID: 30037762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.
    Fisher VS
    J Manag Care Pharm; 2005; 11(1):33-55. PubMed ID: 15667232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
    Lee S; Xie L; Wang Y; Vaidya N; Baser O
    J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies.
    Lasagni C; Bigi L; Conti A; Pellacani G
    J Dermatolog Treat; 2018; 29(sup2):5-8. PubMed ID: 30403898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
    Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
    Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.